VTYX vs. NATR, ME, CRMD, RANI, AQST, XOMA, VNDA, NLTX, INZY, and URGN
Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Nature's Sunshine Products (NATR), 23andMe (ME), CorMedix (CRMD), Rani Therapeutics (RANI), Aquestive Therapeutics (AQST), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), Inozyme Pharma (INZY), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical preparations" industry.
Nature's Sunshine Products (NASDAQ:NATR) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of 0.00%. Ventyx Biosciences' return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
Nature's Sunshine Products presently has a consensus price target of $24.00, indicating a potential upside of 53.85%. Ventyx Biosciences has a consensus price target of $21.75, indicating a potential upside of 359.83%. Given Nature's Sunshine Products' higher probable upside, analysts plainly believe Ventyx Biosciences is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.
Nature's Sunshine Products received 134 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 62.89% of users gave Nature's Sunshine Products an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
In the previous week, Ventyx Biosciences had 4 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 6 mentions for Ventyx Biosciences and 2 mentions for Nature's Sunshine Products. Ventyx Biosciences' average media sentiment score of 1.90 beat Nature's Sunshine Products' score of 0.28 indicating that Nature's Sunshine Products is being referred to more favorably in the media.
79.4% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 4.7% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Nature's Sunshine Products has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Summary
Nature's Sunshine Products beats Ventyx Biosciences on 12 of the 17 factors compared between the two stocks.
Get Ventyx Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ventyx Biosciences Competitors List
Related Companies and Tools
